IL142852A0 - A COMPLEX OF A CHAPERONE WITH β-AMYLOID AND METHODS EMPLOYING THIS COMPLEX - Google Patents

A COMPLEX OF A CHAPERONE WITH β-AMYLOID AND METHODS EMPLOYING THIS COMPLEX

Info

Publication number
IL142852A0
IL142852A0 IL14285299A IL14285299A IL142852A0 IL 142852 A0 IL142852 A0 IL 142852A0 IL 14285299 A IL14285299 A IL 14285299A IL 14285299 A IL14285299 A IL 14285299A IL 142852 A0 IL142852 A0 IL 142852A0
Authority
IL
Israel
Prior art keywords
disease
complex
level
alzheimer
amyloid
Prior art date
Application number
IL14285299A
Other languages
English (en)
Original Assignee
Holtzman Jordan L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Holtzman Jordan L filed Critical Holtzman Jordan L
Publication of IL142852A0 publication Critical patent/IL142852A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14285299A 1998-10-30 1999-10-29 A COMPLEX OF A CHAPERONE WITH β-AMYLOID AND METHODS EMPLOYING THIS COMPLEX IL142852A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10639898P 1998-10-30 1998-10-30
US12356499P 1999-03-10 1999-03-10
PCT/US1999/025593 WO2000026251A2 (en) 1998-10-30 1999-10-29 A COMPLEX OF A CHAPERONE WITH ss-AMYLOID AND METHODS EMPLOYING THIS COMPLEX

Publications (1)

Publication Number Publication Date
IL142852A0 true IL142852A0 (en) 2002-03-10

Family

ID=26803625

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14285299A IL142852A0 (en) 1998-10-30 1999-10-29 A COMPLEX OF A CHAPERONE WITH β-AMYLOID AND METHODS EMPLOYING THIS COMPLEX
IL142852A IL142852A (en) 1998-10-30 2001-04-29 Complex of a chaperone q2 with beta-amyloid and methods employing this complex

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL142852A IL142852A (en) 1998-10-30 2001-04-29 Complex of a chaperone q2 with beta-amyloid and methods employing this complex

Country Status (12)

Country Link
US (3) US6972318B1 (de)
EP (1) EP1125135B1 (de)
JP (1) JP4571310B2 (de)
AT (1) ATE284538T1 (de)
AU (1) AU764713B2 (de)
CA (1) CA2348545C (de)
DE (1) DE69922535T2 (de)
IL (2) IL142852A0 (de)
MX (1) MXPA01004317A (de)
NO (1) NO331974B1 (de)
NZ (1) NZ511589A (de)
WO (1) WO2000026251A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02011675A (es) * 2000-05-24 2004-07-30 Jordan Loyal Holtzman Agentes y metodos para incrementar los niveles de chaperonin en el cerebro.
US7094757B2 (en) 2001-06-22 2006-08-22 Roche Diagnostics Corporation Complexes comprising a prion protein and a peptidyl prolyl isomerase chaperone, and method for producing and using them
US7094884B2 (en) 2001-06-22 2006-08-22 Roche Diagnostics Corporation Soluble complexes of amylod β peptide and peptidyl prolyl isomerase chaperone and methods of making and using them
US6962982B2 (en) 2001-06-22 2005-11-08 Roche Diagnostics Corporation Soluble complexes of target proteins and peptidyl prolyl isomerase chaperones and methods of making and using them
ATE374784T1 (de) * 2002-12-20 2007-10-15 Hoffmann La Roche Lösliche komplexe von zielproteinen und peptidyl- prolyl-isomerase-chaperonen sowie deren herstellung und verwendung
US9335331B2 (en) * 2005-04-11 2016-05-10 Cornell Research Foundation, Inc. Multiplexed biomarkers for monitoring the Alzheimer's disease state of a subject
JP4981305B2 (ja) * 2005-11-11 2012-07-18 公益財団法人大阪バイオサイエンス研究所 アルツハイマー病の発症リスク又はアルツハイマー病発症予後の予測方法
JP2012049495A (ja) * 2010-01-29 2012-03-08 Nitto Denko Corp 発光ダイオード装置
WO2012138284A1 (en) 2011-04-05 2012-10-11 Alphabeta Ab Amyloidosis target useful in methods of treatment and for screening of compounds
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
WO2014012108A1 (en) * 2012-07-13 2014-01-16 Holtzman Jordan L Cellular and animal models for screening therapeutic agents for the treatment of alzheimer's disease
US20180099024A1 (en) * 2016-10-06 2018-04-12 Ramp Research, Llc Methods, compositions, and kits involving alteration of the chaperone protein axis in a subject

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223482A (en) 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
US5780587A (en) * 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US5750349A (en) * 1993-01-25 1998-05-12 Takeda Chemical Industries Ltd. Antibodies to β-amyloids or their derivatives and use thereof
US5707821A (en) 1995-06-07 1998-01-13 Athena Neurosciences, Inc. Identification of phospholipase A2 inhibitors in Aβ peptide-mediated neurodegenerative disease
JPH09178743A (ja) * 1995-12-27 1997-07-11 Oriental Yeast Co Ltd 可溶性ａｐｐの定量法
JP2001525390A (ja) 1997-12-10 2001-12-11 エヌピーエス ファーマシューティカルズ インコーポレーテッド 抗痙攣薬および中枢神経系活性ビス（フルオロフェニル）アルキルアミド類

Also Published As

Publication number Publication date
WO2000026251A2 (en) 2000-05-11
CA2348545C (en) 2012-08-21
ATE284538T1 (de) 2004-12-15
US20110256569A1 (en) 2011-10-20
NO331974B1 (no) 2012-05-14
IL142852A (en) 2010-05-31
US7927824B2 (en) 2011-04-19
AU764713B2 (en) 2003-08-28
NO20012114L (no) 2001-06-14
AU1810500A (en) 2000-05-22
NO20012114D0 (no) 2001-04-27
EP1125135A2 (de) 2001-08-22
US8211658B2 (en) 2012-07-03
NZ511589A (en) 2005-02-25
JP4571310B2 (ja) 2010-10-27
WO2000026251A3 (en) 2000-08-10
WO2000026251A9 (en) 2001-01-04
MXPA01004317A (es) 2003-06-06
EP1125135B1 (de) 2004-12-08
DE69922535T2 (de) 2005-05-12
US6972318B1 (en) 2005-12-06
JP2002528555A (ja) 2002-09-03
US20060024759A1 (en) 2006-02-02
CA2348545A1 (en) 2000-05-11
DE69922535D1 (de) 2005-01-13

Similar Documents

Publication Publication Date Title
Oka et al. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin‐reactive α‐fetoprotein 1
IL142852A0 (en) A COMPLEX OF A CHAPERONE WITH β-AMYLOID AND METHODS EMPLOYING THIS COMPLEX
EP2339348A3 (de) Verfahren zur Diagnose neurodegenerativer Erkrankungen
Gümüşay et al. Diagnostic potential of serum direct markers and non‐invasive fibrosis models in patients with chronic hepatitis B
El-Mezayen et al. Diagnostic performance of collagen IV and laminin for the prediction of fibrosis and cirrhosis in chronic hepatitis C patients: a multicenter study
Giannelli et al. SCCA antigen combined with alpha‐fetoprotein as serologic markers of HCC
BR9916407A (pt) Detecção e tratamento de doenças dos rins
WO2004020968A3 (en) Mutations in nod2 are associated with fibrostenosing disease in patients with crohn’s disease
CY1109062T1 (el) Μεθοδοι ανιχνευσεως και αναστολης της αγγειογενεσεως
Greaves et al. Laboratory testing for heritable thrombophilia: impact on clinical management of thrombotic disease.
IL142971A0 (en) S100 proteins and autoantibodies as serum markers for cancer
WO2007015113A3 (en) New protein isoforms of the pif-family and uses thereof
Papageorgiou et al. Serum levels of vascular endothelial growth factor in non-alcoholic fatty liver disease
Świderska et al. Serum cytokeratin 18 M30 levels in chronic hepatitis B reflect both phase and histological activities of disease
ATE139803T1 (de) Allelische verbindung des humanen dopamin- (d2)rezeptor-gens in kompulsionsstörungen wie alkoholismus
KR102591417B1 (ko) 대변 모니터링 및 건강 지도 장치
Morange et al. Ala147Thr and C+ 1542G polymorphisms in the TAFI gene are not asssociated with a higher risk of venous thrombosis in FV Leiden carriers
Malcolm et al. Carbohydrate-deficient transferrin and alcohol use in medical examiner cases
FI990380A (fi) Diagnostinen ja seulontamenetelmä
JP2006300689A (ja) 肝疾患病態判定用マーカー及び該マーカーを用いる肝疾患病態判定方法
DE68928106D1 (de) Nachweis, quantifizierung und klassifizierung von ras-proteinen in körperflüssigkeiten und geweben
AU2003233292A8 (en) Protein c polymorphisms
EP0563244A4 (en) Human phospholipase activating protein and methods for diagnosis of rheumatoid arthritis
Casonato et al. Which assay is the most suitable to investigate von Willebrand factor functional activity?
EDWARDS Early detection of hereditary hemochromatosis